Fast-Tracked Commercial Development driven by Symbiotic Expertise in Clinical Practice, Biochemistry, and Bioinformatics

2022
Global Business Expansion and Release of MRD Detection Platform

Accelerated clinical adoption of AlphaLiquid® 100
International companion diagnostics partnership with AstraZeneca
Expansion into EU/South America/Southeast Asia/Middle East
Launch of AlphaLiquid® 100 (tissue biopsy test)
Launch of AlphaLiquid® Detect
Analytical validation for AlphaLiquid® Screening
CAP accreditation (ongoing)

2021
Technology Commercialization

Launched AlphaLiquid® 100 in Korea and Taiwan
Companion diagnostics partnership with Korean and European biopharmas
Launched clinical study for AlphaLiquid® Detect
Continued development of AlphaLiquid® Screening Series B investment

2020
Technical Advancement and Portfolio Expansion

Completed development of AlphaLiquid® 100
Started development of AlphaLiquid® Detect and AlphaLiquid® Screening
Series A investment

2018 ~ 2019
Company Established

Incorporated based on NGS-based technologies co-developed by Dr. Tae-You Kim and Dr. Duhee Bang in 2014-17
Transfer of key technologies from Yonsei University
Pre-Series A investment

The #1 Liquid Biopsy Platform Provider in Korea
The most widely adopted liquid biopsy platform in Korea across 20 major hospital with nationwide coverage.

With our commitment to deliver the most reliable services and highest satisfaction for our clients, IMBdx holds various domestic and international certifications that ensure rigorous lab management, quality assays and consistent test results.

GMP certification to ensure that our quality management system applies to the entire process of design, development, production, and post-marketing, such that our products and services are safe, effective, and suitable for their intended use.
ISO 13485 certification ensures the production of safe and quality products in order to comply with the various quality management requirements for medical devices.
AlphaLiquid? 100 complies with the European In Vitro Diagnostic Directive (98/79/EC) and obtained the CE mark for sales in the European market.
Molecular genetic testing services provided by IMBdx have been verified by the Korean Institute of Genetic Testing and Evaluation for reliability and accuracy.

Research Services

Applicable Cancer Types